Review Article

Atrial Fibrillation and Cardiovascular Risk Assessment among COVID-19 Patients Using Different Scores

Authors: Md Mashiul Alam, MBBS, MD, Timir Paul, MD, PhD, Samira Hayee, MBBS, Fatema Mahjabeen, MBBS

Abstract

Since the advent of severe acute respiratory syndrome-coronavirus-2 in December 2019, millions of people have been infected and succumbed to death because of this deadly virus. Cardiovascular complications such as thromboembolism and arrhythmia are predominant causes of morbidity and mortality. Different scores previously used for atrial fibrillation (AF) identification or prediction of its complications were investigated by physicians to understand whether those scores can predict in-hospital mortality or AF among patients infected with the severe acute respiratory syndromecoronavirus-2 virus. Using such scores gives hope for early prediction of atrial arrhythmia and in-hospital mortality among coronavirus disease 2019–infected patients. We have discussed the mechanisms of AF and cardiovascular damage in coronavirus disease 2019 patients, different methods of AF prediction, and compared different scores for prediction of in-hospital mortality after this viral infection.

 
Posted in: Infectious Disease149

Full Article

Having trouble viewing the article content below? Click here to open it directly.

References

1. Worldometer. COVID-19 coronavirus pandemic. https://www.worldometers.info/coronavirus/. Accessed April 1, 2022.
 
2. Promislow DEL. A geroscience perspective on COVID-19 mortality. J Gerontol A Biol Sci Med Sci 2020;75:e30–e33.
 
3. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020;116:1666–1687.
 
4. Pieralli F, Biondo B, Vannucchi V, et al. Performance of the CHA(2)DS(2)- VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. Eur J Intern Med 2019;62:24–28. .
 
5. Yang HJ, Wang GJ, Shuai W, et al. The value of the CHADS(2) and CHA(2) DS(2)-VASc score for predicting the prognosis in lacunar stroke with or without atrial fibrillation patients. J Stroke Cerebrovasc Dis 2019;28: 1041–43.
 
6. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in northern Italy. Eur Heart J 2020;41:1821–1829.
 
7. Gawałko M, Kapłon-Cieślicka A, Hohl M, et al. COVID-19 associated atrial fibrillation: incidence, putative mechanisms and potential clinical implications. IJC Heart Vasc 2020;30:100631.
 
8. Stone E, Kiat H, McLachlan CS. Atrial fibrillation in COVID-19: a review of possible mechanisms. FASEB J 2020;34:11347–11354.
 
9. Pardo Sanz A, Salido Tahoces L, Ortega Pérez R, et al. New-onset atrial fibrillation during COVID-19 infection predicts poor prognosis. Cardiol J 2021;28:34–40.
 
10. Romiti GF, Corica B, Lip GYH, et al. Prevalence and impact of atrial fibrillation in hospitalized patients with COVID-19: a systematic review and meta-analysis. J Clin Med 2021;10:2490.
 
11. Zuin M, Rigatelli G, Bilato C, et al. Pre-existing atrial fibrillation is associated with increased mortality in COVID-19 patients. J Interv Card Electrophysiol 2021;2:231–238.
 
12. Atkins JL, Masoli JAH, Delgado J, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci 2020;75:2224–2230.
 
13. Chilimuri S, Sun H, Alemam A, et al. Predictors of mortality in adults admitted with COVID-19: retrospective cohort study from New York City. West J Emerg Med 2020;21:779–784.
 
14. Lanza GA, De Vita A, Ravenna SE, et al. Electrocardiographic findings at presentation and clinical outcome in patients with SARS-CoV-2 infection. Europace 2021;23:123–129.
 
15. Lovicu E, Faraone A, Fortini A. Admission Braden Scale score as an early independent predictor of in-hospital mortality among inpatients with COVID-19: a retrospective cohort study. Worldviews Evid Based Nurs 2021;18:247–253.
 
16. Quisi A, Alici G, Harbalioglu H, et al. The CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19: a multicenter retrospective cohort study. Turk Kardiyol Dern Ars 2020;48:656–663.
 
17. Abacioglu OO, Yildirim A. The ATRIA score is superior to the m-CHA2DS2- Vasc score in predicting in-hospital mortality in COVID-19. Rev Assoc Med Bras 2021;67:443–448.
 
18. Aciksari G, Cetinkal G, Kocak M, et al. Evaluation of modified ATRIA risk score in predicting mortality in hospitalized patients with COVID-19. Am J Med Sci 2021;362:553–561.
 
19. Halalau A, Imam Z, Karabon P, et al. External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients. Ann Med 2021;53:78–86.
 
20. Uribarri A, Nunez-Gil IJ, Aparisi A, et al. Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry. Rev Esp Cardiol (Engl Ed) 2021; 74:608–615.
 
21. Caro-Codón J, Lip GYH, Rey JR, et al. Prediction of thromboembolic events and mortality by the CHADS2 and the CHA2DS2-VASc in COVID-19. Europace 2021;23:937–947.
 
22. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049–1056.
 
23. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012;107:1172–1179.
 
24. Naccarelli GV, Panaccio MP, Cummins G, et al. CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. Am J Cardiol 2012;109:1526–1533.
 
25. Moss TJ, Calland JM, Enfield KB, et al. New-onset atrial fibrillation in the critically ill. Crit Care Med 2017;45:790–797.
 
26. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142–1147.
 
27. Zuo H, Nygard O, Ueland PM, et al. Association of plasma neopterin with risk of an inpatient hospital diagnosis of atrial fibrillation: results from two prospective cohort studies. J Intern Med 2018;283:578–587.
 
28. Klouwenberg PMCK, Frencken JF, Kuipers S, et al. Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis. A cohort study. Am J Respir Crit Care Med 2017;195:205–211.
 
29. Kelesoglu S, Yilmaz Y, Ozkan E, et al. New onset atrial fibrilation and risk faktors in COVID-19. J Electrocardiol 2021;65:76–81.
 
30. Bosch NA, Cimini J, Walkey AJ. Atrial fibrillation in the ICU. Chest 2018; 154:1424–1434.
 
31. Li YG, Pastori D, Farcomeni A, et al. A simple clinical risk score (C(2) HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects. Chest 2019;155:510–518.
 
32. Hu WS, Lin CL. Comparison of CHA2DS2-VASc and C2HEST scores for predicting the incidence of atrial fibrillation among patients with end-stage renal disease. Perfusion 2020;35:842–846.
 
33. de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725–31.
 
34. Hsieh CY, Lee CH, Wu DP, et al. Prediction of new-onset atrial fibrillation after first-ever ischemic stroke: a comparison of CHADS 2, CHA 2 DS 2 -VASc and HATCH scores and the added value of stroke severity. Atherosclerosis 2018; 272:73–79.
 
35. Proietti M, Marzona I, Vannini T, et al. Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use. Mayo Clin Proc 2019;94:2427–2436.
 
36. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 2010;137:263–272.